Related Experiment Video

Updated: Jun 23, 2026

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

Impaired fasting glucose and cardiogenic shock in patients with acute myocardial infarction

Marianne Zeller1, Yves Cottin, Marie-Claude Brindisi

  • 1Service de Cardiologie, CHU Bocage, Dijon, France. marianne.zeller@u-bourgogne.fr

European Heart Journal
|February 27, 2004
PubMed

Insights

Patients with Impaired Fasting Glucose (IFG) after acute myocardial infarction (MI) face worse outcomes. This includes a doubled mortality risk and increased cardiogenic shock compared to those with normal fasting glucose (NFG).

Area of Science:

  • Cardiology
  • Endocrinology
  • Metabolic Syndrome

Background:

  • In-hospital outcomes for acute myocardial infarction (MI) patients have not been fully assessed for the Impaired Fasting Glucose (IFG) category.
  • The American Diabetes Association (ADA) has defined new categories for glucose levels, including IFG.

Purpose of the Study:

  • To evaluate the in-hospital outcomes of acute myocardial infarction (MI) patients categorized by Impaired Fasting Glucose (IFG) levels.
  • To determine if IFG is an independent predictor of adverse outcomes post-MI.

Main Methods:

  • A cohort of 999 acute MI patients from the RICO survey was analyzed.
  • Patients were classified into Diabetes Mellitus (DM), IFG (fasting glucose 6.1-7 mmol/l), and Normal Fasting Glucose (NFG) groups based on ADA criteria.
  • In-hospital outcomes, including mortality, cardiogenic shock, and ventricular arrhythmia, were compared between groups.

Main Results:

  • 15% of patients had IFG, 38% had DM, and 47% had NFG.
  • The IFG group showed twice the mortality rate (8% vs 4%) compared to the NFG group (P=0.049).
  • IFG patients experienced significantly higher rates of cardiogenic shock (12% vs 6%, P=0.011) and ventricular arrhythmia (15% vs 9%, P=0.035).
  • IFG was identified as an independent predictor of cardiogenic shock after adjusting for confounding factors.

Conclusions:

  • Acute myocardial infarction patients with Impaired Fasting Glucose exhibit a worse overall in-hospital outcome.
  • There is a significantly higher risk of developing cardiogenic shock among MI patients with IFG during hospitalization.
Abstract

More Related Videos

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

Related Concept Videos

Overview of Carbohydrate Metabolism01:19

Overview of Carbohydrate Metabolism

Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...